Search - tctmd.com

Displaying 1 - 20 of 73

Sort: Relevancy | Date

Year in Review: Top Prevention Stories of 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

News Daily News

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Michael O'Riordan

June 04, 2024

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

March 27, 2024

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

News Daily News

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

February 14, 2024

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

November 13, 2023

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

September 19, 2023

TCTMD’s Michael O’Riordan Wins Digital Health Award

News Daily News

TCTMD’s Michael O’Riordan Wins Digital Health Award

August 22, 2023

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

Longer-Term ASCVD Risk Assessment Best for Younger Patients

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

January 2023 News Roundup

News Opinion CV Team Dispatch

January 2023 News Roundup

January 16, 2023

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.